Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 20 of 30

TERMINATED Phase 2

The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)

NCT02145299

COMPLETED Phase 4

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011

COMPLETED

Allocentric Memory in MS and Resting State Functional MRI

NCT02118298

COMPLETED NA

Project Wellness Enhancement: Increasing Health Care Choice and Outcomes for People With Mental Illness

NCT02263742

COMPLETED NA

Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II

NCT02501967

TERMINATED Phase 2

A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction

NCT02044302

COMPLETED NA

The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users

NCT02102100

COMPLETED Phase 2

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

NCT02047474

COMPLETED Phase 1

Neuroimmune Response to Lipopolysaccharide

NCT04233593

COMPLETED Phase 2

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

NCT02085070

COMPLETED Phase 2

Guanfacine Clinical Trial for Smoking Cessation

NCT02051309

COMPLETED NA

Pain Management for Veterans Filing Compensation Claims

NCT02049086

TERMINATED NA

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284

COMPLETED NA

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

NCT02069925

COMPLETED Phase 1

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

NCT02124941

COMPLETED Phase 2

Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma

NCT02007954

COMPLETED

Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance

NCT02109094

COMPLETED Phase 2

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer

NCT02015754

COMPLETED NA

Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me"

NCT02169024

COMPLETED

AbATE Follow-Up Study

NCT02067923

TERMINATED NA

CHG Dressings in Children With Central Lines

NCT01955226

COMPLETED

Evaluation of the Office on Violence Against Women's Domestic Violence Homicide Prevention Demonstrative Initiative

NCT02021838

COMPLETED NA

A Pilot Study of Dietary Chloride Supplementation on Cardiorenal Function in Heart Failure

NCT02031354

COMPLETED NA

CBT for Spanish Speakers

NCT02043210

COMPLETED Phase 1

A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

NCT02019940

COMPLETED NA

Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer

NCT02057029

COMPLETED NA

A Study to Help People Quit Smoking.

NCT01880099

TERMINATED NA

Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.

NCT02005705

COMPLETED NA

Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents

NCT01965184

COMPLETED Phase 2

Progesterone for Smoking Relapse Prevention Following Delivery

NCT01972464

COMPLETED NA

Lifestyle, Exercise and Nutrition Study 2 (LEAN 2)

NCT02110641

TERMINATED NA

A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection

NCT02005614

COMPLETED NA

Family Based Mindfulness Intervention

NCT01974102

COMPLETED NA

The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

NCT01976156

COMPLETED Phase 1

Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans

NCT02018263

TERMINATED Phase 2

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

NCT01977729

COMPLETED Early Phase 1

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099

COMPLETED Phase 2

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

NCT01855828

COMPLETED NA

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

NCT02008292

COMPLETED Phase 2

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329

TERMINATED Early Phase 1

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

NCT01954459

COMPLETED Early Phase 1

Digestive Endoscopy Suite Radiation Controlling Protective Strategies

NCT02063841

COMPLETED NA

The Role of Emotional Arousal in Food Preference and Taste

NCT02402088

COMPLETED NA

Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers

NCT01691105

COMPLETED

Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)

NCT01925586

COMPLETED Phase 2

Translational Neuroscience Optimization of GlyT1 Inhibitor

NCT01911676

COMPLETED Phase 1

The Effects of Minocycline in Humans

NCT02193269

COMPLETED NA

The Gut-brain Axis in Food Reward and Alcohol Consumption

NCT01902069

COMPLETED

MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research

NCT02313623

COMPLETED Early Phase 1

Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

NCT02037035

← Previous Page 20 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.